Interpace can now offer the new service alone or in conjunction with ThyGenX next-generation sequencing oncogene panel in New York.
The agency said that its action on MSK IMPACT "advances a policy framework that paves the way for the efficient review and availability of other NGS-based cancer profiling tools."
The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.
The New York State Clinical Laboratory Evaluation Program has approved the company's FoundationACT blood-based circulating tumor DNA assay.
The firm said it will offer 25 million units consisting of common stock and common warrants at $.40 per unit.
The company's Acuitas test provides information on the presence of 10 MDRO resistance genes in a single sample.
The tests were previously available in New York state on a patient-by-patient basis through a non-permitted laboratory testing program.
The tests are all based on the company's dual-capture, dual-sequencing platform method.
The company also announced that it has received New York State Department of Health conditional approval for three women's health molecular diagnostic tests.
Guardant said Guardant360 is the first liquid biopsy permitted by New York's CLEP, and the approval means the test can be ordered in all 50 states.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.